本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- DAIICHI, a leading car seat company in Korea, has launched the portable car seat 'Easy Carry 2' and portable stroller 'The Space' in Indonesia, optimized for travel and meet safety and convenience. DAIICHI is the No. 1 car seat manufacturer in Korea with a 50% market share. Founded in 2001, DAIICHI is a car seat company that is loved by customers for its made in Korea car seats called the 'national car seat' in Korea. In addition, DAIICHI is a baby products company solidifying its position in the global market by selling car seats in more than 100 offline stores in Korea and exporting to 12 countries including Japan, Thailand, Indonesia, Singapore, and Romania. DAIICHI has been the main sponsor for numerous TV dramas, movies, and entertainment programs, and in particular, DAIICHI supported the production of the drama <Spring Night>, which was recently loved by Netflix, starring Jung Hae-in, and also promoted DAIICHI products through entertainment programs such as <Dad, Where Are We Going> and <The Return of Superman>. A DAIICHI representative stated, "Indonesia is one of the countries with the most islands in the world, and since travel is a part of daily life, there are many families traveling with children. DAIICHI developed these products to provide safe and convenient travel for these families, and we expect that these products, which have applied Korea's high quality standards, will be loved by Indonesian parents." Portable strollers optimized for Indonesia The portable stroller 'The Space' is an ultra-lightweight design that can be carried on board, so there is no need to check the stroller in as luggage when traveling, and it is easy for parents to carry it, and it is an automatic folding stroller that automatically folds with the click of a button with one hand. Also, since it is a portable stroller with perfect handling, folding, and even a basket car seat combination, it is expected to be very popular in Indonesia, where people travel and move frequently. DAIICHI's portable car seat 'Easy Carry 2' and 'The Space' portable stroller can be found at the DAIICHI Premium booth located at the IMBEX exhibition hall (Jakarta convention center) from November 29 to December 1, 2024, and can also be seen at Plaza Senayen mall.
SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- FinVolution Group ("FinVolution," or the "Company") (NYSE: FINV), a leading fintech platform, today announced that its Indonesian financial application, AdaKami, has entered into a strategic funding agreement with PT Super Bank Indonesia, a leading digital-focused bank in Indonesia. Under the terms of the agreement, Superbank will provide AdaKami with a funding facility of 500.0 billion Rupiah (approximately US$32.0 million). This funding arrangement highlights AdaKami's recognition by a leading local bank following its successful transition to serving better-quality borrowers. With this agreement, Superbank will become AdaKami's strong funding partner in Indonesia, validating Adakami's successful strategy of transition to better-quality borrowers. Currently, AdaKami has established cooperation with multiple lenders including Superbank, Seabank, Bank Jago, Bank Permata, OCBC NISP among others. Mr. Tiezheng Li, Vice Chairman and Chief Executive Officer of FinVolution Group, commented, "We are proud to collaborate with Superbank to serve our growing customer base in Indonesia. With our transition to better-quality borrowers, we continue to attract reputable partners in the region, strengthening our reputation while diversifying our funding sources and improving our funding costs. By expanding our footprint and strengthening our local relationships, we are steadily advancing our mission of promoting financial inclusion while growing our business." About FinVolution Group FinVolution Group is a leading fintech platform with strong brand recognition in China and the international markets connecting borrowers of the young generation with financial institutions. Established in 2007, the Company is a pioneer in China's online consumer finance industry and has developed innovative technologies and accumulated in-depth experience in the core areas of credit risk assessment, fraud detection, big data and artificial intelligence. The Company's platforms, empowered by proprietary cutting-edge technologies, feature a highly automated loan transaction process, which enables a superior user experience. As of June 30, 2024, the Company had over 191.3 million cumulative registered users across China, Indonesia and the Philippines. About PT Super Bank Indonesia Superbank, formerly known as PT Bank Fama International, is a bank with digital services in Indonesia with over 2 million customers as of October 2024. Founded in Bandung in 1993, Superbank entered a new era of growth joining the Emtek Group in 2021, followed by Grab and Singtel in early 2022, and KakaoBank in 2023 as part of the consortium. With a mission to expand credit access for retail customers and MSMEs, Superbank empowers its users through innovative solutions and strong collaborations within one of the largest ecosystems in the industry. Superbank's commitment to security is evidenced by its ISO 27001 certification, ensuring international standards in information security. For investor and media inquiries, please contact: In China:FinVolution GroupHead of Investor RelationsJimmy Tan, IRCTel: +86 (21) 8030-3200 Ext. 8601E-mail: ir@xinye.com Piacente Financial CommunicationsJenny CaiTel: +86 (10) 6508-0677E-mail: finv@tpg-ir.com In the United States:Piacente Financial Communications Brandi PiacenteTel: +1-212-481-2050E-mail: finv@tpg-ir.com
- First order for a facility operated by Star Energy Group, Indonesia's largest geothermal power producer - KAWASAKI, Japan, Oct. 24, 2024 /PRNewswire/ -- Toshiba Energy Systems & Solutions Corporation (Toshiba) today announced that is has received an order to supply a steam turbine and a generator from PT Inti Karya Persada Tehnik (IKPT), a subsidiary of Toyo Engineering Corporation, and EPC* contractor for the expansion of the Wayang Windu Geothermal Power Plant Unit 3, operated by Star Energy Geothermal (Wayang Windu) Limited in West Java, Indonesia. Toshiba has a long history of providing power generation equipment for geothermal plants in Indonesia, but this marks the first time the company will supply equipment for a geothermal plant operated by Star Energy Group, the country's largest geothermal power producer. Toshiba was selected for its proven track record and the superior performance of its equipment. Indonesia, the world's second largest producer of geothermal power, is rich in geothermal resources, with an estimated capacity of approximately 30GW. Demand for electricity is surging as Indonesia's economy grows. While the government shares concerns over global environmental issues, and aims to achieve carbon neutrality by 2060, it must also expand power generation capacity. Under its latest "Electricity Supply Business Plan (RUPTL 2021-2030)" the government aims to increase power generation capacity by approximately 40.6GW by 2030, with geothermal power contributing 3.35GW, approximately 8% of the total. This includes expansion of Wayang Windu, with 2026 targeted for the start of operations. Toshiba has contributed to stable power supply in Indonesia with the delivery of six steam turbines and generators for geothermal plants with a combined capacity of 311MW. This includes equipment for the Sarulla Geothermal Power Plant, one of the country's largest geothermal facilities, and for the Patuha Geothermal Power Plant Unit 1. Takehiko Matsushita, Vice President of the Power Systems Division at Toshiba, commented: "We are delighted to have been selected to supply key equipment for the Wayang Windu expansion project, and I am confident that, once installed, the performance and reliability of our steam turbine and generator will demonstrate that we are a reliable partner for all kinds of geothermal projects. We have an extensive geothermal product lineup, ranging from 1MW to 200MW, and have executed numerous projects in Japan and overseas, helping our customers to make use of a constant and clean source of energy. We will continue to develop and promote geothermal solutions that support a sustainable future." Project outlineName of Power Plant: Wayang Windu Geothermal Power PlantOwner: Star Energy Geothermal (Wayang Windu) LimitedScope of Toshiba's supply: Steam turbine and generator for unit 3 (power generation capacity: 30MW)Scheduled start of operation: 2026 Note: Engineering Procurement and Construction
This approval paves the way for exports to the world's fourth most populous country. SK bioscience aims to continue to grow as a global vaccine brand beyond Korea by leveraging the advantages of cell-cultured vaccines. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that Indonesia's Food and Drug Agency, BPOM (Badan Pengawas Obat dan Makanan), has approved the Biologics License Application (BLA) for the SKYCellflu Quadrivalent prefilled syringe, the world's first quadrivalent cell-cultured influenza vaccine. This is the first time a domestically made influenza vaccine has received approval in Indonesia. SKYCellflu Quadrivalent prefilled syringe Indonesia is the world's fourth most populous nation with over 280 million people, with rapidly growing pharmaceutical market. According to global market research firm Innsight10, Indonesia's flu vaccine market is projected to grow from USD 38.5 million in 2022 to USD 69.1 million in 2030. Due to its elongated geography, spanning both Northern and Southern Hemispheres, Indonesia is impacted by the World Health Organization's flu vaccination guidelines for both regions. Following this approval of SKYCellflu for the Northern Hemisphere influenza strains, SK bioscience anticipates fast-tracked approval of flu vaccine for Southern Hemisphere influenza strains by the Indonesian Food and Drug Agency. SKYCellFlu is the world's first cell culture-based influenza vaccine to achieve WHO Prequalification (PQ) certification, demonstrating acceptable immunogenicity and safety across clinical trials. It is the only cell-cultured influenza vaccine currently available in Korea. Compared to the egg-based vaccines, its shorter production timeline makes it more suited for rapid response to pandemics or the emerging variants. SKYCellflu also does not require antibiotic or preservative administration. In addition, cell-cultured vaccines are less likely to mutate during the production process than those produced in fertilized eggs, allowing for a more accurate match to circulating influenza strains. In SK bioscience's research, the company conducted subcultures 15 times by employing cells for SKYCellflu production and fertilized eggs. Subculturing, also referred to as passaging cells, is the removal of the medium and transfer of cells from a previous culture into fresh growth medium, a procedure that enables the further propagation of the cell line or cell strain. The study results showed that mutations were found in three proteins within the virus in the fertilized egg method, while no mutations were found in the cells used for SKYCellflu production. These findings were presented at the 2019 Korea Interscience Working Group on Influenza (KIWI) Symposium. SKYCellflu has already been approved in multiple Asian countries, including Malaysia, Thailand, Myanmar, Iran, Singapore, Pakistan, Mongolia, and Brunei. Last year, it was granted in Chile, marking its first approval in the South American market. SK bioscience plans to pave the way for a full-scale expansion into global export markets. Jaeyong Ahn, CEO of SK bioscience, said, "It is very encouraging that our own developed vaccines are receiving approvals worldwide, a significant step for expanding our global export market." He added, "We are confident that SK bioscience will continue to grow into a global vaccine brand beyond Korea, as our vaccines, including shingles, chickenpox, and typhoid vaccines, are securing WHO PQ certifications and global approvals one after another." About SK bioscience SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.- SK bioscience Website- SK bioscience Linkedin ContactSK bioscience Communications TeamChanghyun Jin(jin99@sk.com) Jeannie S. Pak(j.pak@sk.com)
This approval paves the way for exports to the world's fourth most populous country. SK bioscience aims to continue to grow as a global vaccine brand beyond Korea. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that Indonesia's Food and Drug Agency, BPOM (Badan Pengawas Obat dan Makanan), has approved the Biologics License Application (BLA) for the SKYCellflu Quadrivalent prefilled syringe, the world's first quadrivalent cell-cultured influenza vaccine. This is the first time a domestically made influenza vaccine has received approval in Indonesia. SKYCellflu Quadrivalent prefilled syringe Indonesia, the world's fourth most populous nation with over 280 million people, is impacted by the World Health Organization's flu vaccination guidelines for both regions due to its elongated geography, spanning both the Northern and Southern Hemispheres. Following this approval of SKYCellflu for the Northern Hemisphere influenza strains, SK bioscience anticipates fast-tracked approval of flu vaccine for the Southern Hemisphere in Indonesia. SKYCellFlu is the world's first cell culture-based influenza vaccine to achieve WHO Prequalification (PQ) certification, demonstrating acceptable immunogenicity and safety across clinical trials. It is the only cell-cultured influenza vaccine currently available in Korea. Compared to the egg-based vaccines, its shorter production timeline makes it more suited for rapid response to pandemics or the emerging variants. SKYCellflu also doesn't require antibiotic or preservative administration. In addition, cell-cultured vaccines are less likely to mutate during the production process than those produced in fertilized eggs, allowing for a more accurate match to circulating influenza strains. In SK bioscience's research, the company conducted subcultures 15 times by employing cells for SKYCellflu production and fertilized eggs. Subculturing is the removal of the medium and transfer of cells from a previous culture into fresh growth medium, a procedure that enables the further propagation of the cell line or cell strain. The study results showed that mutations were found in three proteins within the virus in the fertilized egg method, while no mutations were found in the cells used for SKYCellflu production. These findings were presented at the 2019 Korea Interscience Working Group on Influenza (KIWI) Symposium. SKYCellflu has already been approved in multiple Asian countries, including Malaysia, Thailand, Myanmar, Iran, Singapore, Pakistan, Mongolia, and Brunei. Last year, it was granted in Chile, marking its first approval in the South American market. SK bioscience plans to pave the way for a full-scale expansion into global export markets. Jaeyong Ahn, CEO of SK bioscience, said, "It is very encouraging that our own developed vaccines are receiving approvals worldwide, a significant step for expanding our global export market." He added, "We are confident that SK bioscience continues to grow into a global vaccine brand beyond Korea, as our vaccines, including shingles, chickenpox, and typhoid vaccines, secures WHO PQ certifications and global approvals one after another." SK bioscience Communications TeamChanghyun Jin (jin99@sk.com) Jeannie S. Pak (j.pak@sk.com)
JAKARTA, Indonesia, Oct. 22, 2024 /PRNewswire/ -- NEC Indonesia and Sinar Mas Land, through its subsidiary PT Samakta Mitra, have started a strategic partnership to mitigate the impact of climate change by leveraging Adaptation Finance and disaster mitigation visualisation technology. Adaptation Finance is an initiative developed by the United Nations Environment Programme (UNEP), designed to assess the risks and impacts of natural disasters caused by climate change. It aims to identify risks early, plan mitigation strategies, and foster greater business resilience. The Memorandum of Understanding (MoU) to begin a joint study on Adaptation Finance in Indonesia between Sinar Mas Land and NEC Indonesia was signed by Irvan Yasni, CEO of Technology Advisory and Business of Sinar Mas Land, and Joji Yamamoto, President Director of NEC Indonesia, at the Biomedical Campus, BSD City, last 15 October 2024. Yutaka Ukegawa, Corporate Executive Vice President of NEC Corporation, and Mulyawan Gani, Chief Transformation & Data Officer of Sinar Mas Land, were also in attendance. Irvan Yasni, CEO of Technology Advisory & Business at Sinar Mas Land (second from the left), together with Joji Yamamoto, President Director of NEC Indonesia (second from the right), signs a Memorandum of Understanding to initiate a joint study on Adaptation Finance in Indonesia, witnessed by Mulyawan Gani, Chief Transformation & Data Officer of Sinar Mas Land (far left), and Yutaka Ukegawa, Corporate Executive Vice President of NEC Corporation (far right). Joji Yamamoto shares, "This collaboration marks an important first step in realising the Adaptation Finance initiative for mitigating the climate change. We believe that the technology and solutions offered by NEC can contribute to developing adaptive financial solutions that can be applied across various sectors. We look forward to this partnership with Sinar Mas Land's subsidiary, PT Samakta Mitra. Previously, NEC implemented the same solutions in Japan, supported by major insurance companies. The success of this endeavour emphasises the significant potential of this collaboration to bring positive impacts to Indonesia's financial services industry, particularly in addressing the growing climate challenges." Irvan Yasni adds, "Adaptation Finance presents a great opportunity to create a more sustainable and safer environment in the face of disaster risks resulting from climate change. Together with NEC Indonesia, we will conduct a joint study on Adaptation Finance to develop case studies that anticipate adaptation steps and solutions to climate change across various sectors. By applying technology with disaster risk and climate change mapping, insurance companies can estimate potential losses and mitigate existing risks, allowing for more effective mitigation efforts." Through this collaboration, Sinar Mas Land and NEC Indonesia will develop risk visualisation solutions capable of mapping the potential for natural disasters such as floods, earthquakes, and tropical cyclones. This will thereby accelerate the adoption of disaster risk mitigation solutions among insurance companies, banks, and investment firms. This initiative also supports better protection for communities and infrastructure in the future. By utilising data-driven solutions, predictive analytics, and artificial intelligence (AI), NEC Indonesia will identify potential threats, assess environmental impacts, and provide more effective risk mitigation recommendations. This technology enables more strategic and sustainable allocation of funds, allowing Adaptation Finance to deliver positive effects on society, the business community, and the environment. (*) About PT NEC Indonesia NEC first established its representative office in Jakarta in 1968. To this day, PT NEC Indonesia continues to play an important role in providing innovative ICT solutions to promote safety, security, and improve the quality of life for individuals and communities. As a leading provider of information and communication technology, PT NEC Indonesia provides world-class services and technology including telecommunications networks, biometric identification, intelligent solutions for Banks and other Financial Services, Public Transportation and Logistics, Retail, Manufacturing, as well as government applications and infrastructure and business enterprises to support the digital transformation journey. For more information, visit us at http://id.nec.com/. About Sinar Mas Land Sinar Mas Land is a property developer in Indonesia with over 50 years of experience. Sinar Mas Land has developed more than 50 projects across Indonesia. The company's success in property and real estate development in Indonesia has been recognized by independent and credible institutions, earning various prestigious international awards such as the MIPIM Award in France (2018), ASEAN Energy Awards (2019), Asia Pacific Property Award (2021), Cambridge IFA's Global Good Governance Award (2021), and FIABCI World Prix d'Excellence Awards (2022). With the support of a solid management team, Sinar Mas Land is renowned as a developer of independent townships (through the BSD City Development) and a pioneer in the development of the clustered residential concept. In addition, Sinar Mas Land is also a trailblazer in the development of innovative Strata Mall/Trade Center (ITC) projects in Indonesia. Sinar Mas Land is listed on the Indonesia Stock Exchange as PT Bumi Serpong Damai Tbk, and on the Singapore Exchange. Sinar Mas Land has strong strategic partners such as Sojitz Japan, Aeon, Itochu, Mitsubishi Corporation, Hongkong Land, and local partners like Kompas Gramedia and Kalbe. For more information, please visit: www.sinarmasland.com.
A12 藝術空間
Indonesia
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
